To evaluate DNA methylation changes associated with IDH-mutant glioma progression, we analyzed the number of DMPs between paired tumors of individual patients (“temporal intratumor DMPs”) and between tumor groups (i.e. unpaired primary vs. recurrent tumors). The gene discussed is IDH2; the disease is central nervous system cancer.